ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
The cost-effectiveness of biosimilar denosumab in postmenopausal osteoporosis: implications of baseline fracture risk and drug price.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biosimilar denosumab is a dominant treatment strategy (i.e., more effective and less costly) across varying levels of baseline fracture risk with sufficient price reductions. Given its superior efficacy and safety, it may be considered a first-line therapy for the treatment of women with postmenopausal osteoporosis at high risk of fracture in the United States (US). Large-scale adoption of biosimilar denosumab as a first-line therapy in this population is anticipated to lead to health improvements at a lower overall cost. PURPOSE: Postmenopausal osteoporosis (PMO) remains undertreated in the US. According to clinical practice guidelines, bisphosphonates and denosumab are recommended therapies for women at high risk of fracture, but bisphosphonates have been preferred due to lower cost. The introduction of biosimilar denosumab may reduce prices and improve access. This study evaluates the cost-effectiveness of biosimilar denosumab compared to bisphosphonates and no intervention in women with PMO in the US across different baseline fracture risks and biosimilar denosumab pricing scenarios.
methodsA validated Markov cohort model estimated cost-effectiveness of biosimilar denosumab versus alendronate, risedronate, ibandronate, zoledronic acid, and no intervention. Patients were stratified into four risk categories based on T-score and prior vertebral fracture. The analyses explored the impact of changes in baseline fracture risk and biosimilar denosumab pricing.
resultsThe cost-effectiveness of biosimilar denosumab improved with increasing fracture risk (categories 1-4 represent increasing risk). Biosimilar denosumab was dominant (i.e., more effective and less costly) when priced at $120-$180, $376-$451, $376-$481, and $857-$1188 for risk categories 1, 2, 3, and 4, respectively. At a 75% price reduction (i.e., $376), biosimilar denosumab was dominant versus all comparators for risk categories 2, 3, and 4.
conclusionWith sufficient price reductions, biosimilar denosumab is a dominant strategy across varying levels of baseline fracture risk. Biosimilar denosumab's superior efficacy and favorable safety profile compared to bisphosphonates, along with anticipated price declines, support its potential as a first-line therapy for women with PMO at high-risk of fracture in the US.
Indexed as
Identifiers
42533098What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.